A new approach in early Alzheimer’s disease research, including Mild Cognitive Impairment and early dementia
The BenfoTeam clinical research trial is based . BenfoTeam scientists have found that thiamine (vitamin B1) does not enter the brains of people with early Alzheimer’s disease despite having a sufficient supply of thiamine in their blood.
Fortunately, there is also evidence that this problem with thiamine in the brain may be overcome by boosting the amount of thiamine in the blood far above usual levels. Benfotiamine, a lab-made version of thiamine, is the drug being tested in the BenfoTeam trial.
BenfoTeam tests if increasing thiamine in the blood slows cognitive decline in people with early Alzheimer’s disease, including Mild Cognitive Impairment (MCI) and mild dementia.
.
Join BenfoTeam!
For any questions email:
adcs-recruitment@health.ucsd.edu
or
Talk to a Prescreener:
Call 877-807-1290